The purpose of the study is to determine if there are differences in the final height or hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now routinely used to increase stature: Anastrozole and Letrozole. It also should determine if there are differences in the side effect profiles of the two drugs to be used.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
79
Lucile Packard Children's Hospital
Palo Alto, California, United States
Predicted Adult Height at Year 3
Heights will be obtained by physical exam every 6 months during treatment. Skeletal maturation will be assessed from an x-ray by the method of Greulich and Pyle at baseline and every 12 months until the end of treatment. Predicted adult height will be calculated at baseline and at the end of treatment based upon measured height and skeletal maturation (bone age).
Time frame: Year 3
Serum Testosterone
Time frame: Baseline, year 3
Dihydrotestosterone
Time frame: Baseline, year 3
Androstenedione
Time frame: Baseline, year 3
Luteinizing Hormone
Time frame: Baseline, year 3
Follicle Stimulating Hormone
Time frame: Baseline, year 3
Insulin-like Growth Factor Type 1
Time frame: Baseline, year 3
Inhibin B
Time frame: Baseline, year 3
Estradiol
Time frame: Baseline, year 3
Estrone
Time frame: Baseline, year 3
Number of Adverse Events Related to Acne or Bone Fracture
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.